It has been well recognized that the mode of action of MPH in ADHD treatment is in its blockade of not only the dopamine transporter (DAT) [5] but also the norepinephrine transporter (NET) [6]. Here, SLC6A2 is linked to attention deficit-hyperactivity disorder.